Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study

Published:2021-11 Issue: Volume:Volume 14 Page:7625-7637
ISSN:1178-7074
Container-title:International Journal of General Medicine
language:en
Short-container-title:IJGM

Author:

Jiang Hong-Tao,Li Wei,Zhang Biao,Gong Qiang,Qie Hai-Ling

Publisher

Informa UK Limited

Subject

General Medicine

Reference40 articles.

1. Do socioeconomic factors modify the effects of PM1 and SO2 on lung cancer incidence in China?

Clinical Significance of Has_circ_0060937 in Bone Metastasis of NSCLC

3. Epidermal Growth Factor in Exhaled Breath Condensate as Diagnostic Method for Non-Small Cell Lung Cancer

4. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer

5. Tumor Angiogenesis: Therapeutic Implications

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer;Frontiers in Oncology;2024-07-16

2. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial;Lung Cancer;2024-05

3. Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial;Frontiers in Oncology;2024-04-08

4. Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study;Lung Cancer: Targets and Therapy;2024-03

5. Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study;Journal of Oncology;2022-07-22